Navigation Links
CleveMed Receives $1.5 Million in NIH Funding to Further Develop a Portable System for Monitoring Parkinson's Disease Motor Symptoms

CLEVELAND, Dec. 19 /PRNewswire/ -- Cleveland Medical Devices Inc. (CleveMed) announced that it has been awarded $1.5 million in NIH SBIR Phase II Continuation funding from the National Institute of Neurological Disorders and Stroke (NINDS). The grant will fund further development and clinical validation of Kinesia(TM), a quantitative motor assessment system for evaluating Parkinson's disease symptom severity. The initiative includes a large multi-center clinical trial with University Hospitals of Cleveland, the University of Cincinnati, and The Clinical Neuroscience Center in Detroit, Michigan as the participating centers. The trial will aid in development of Kinesia for continuous symptom monitoring in patients' homes, as well as further validate the correlation between the device and the Unified Parkinson's Disease Rating Scale (UPDRS).

Kinesia is a compact lightweight system worn on a patient's wrist and hand. The device monitors three-dimensional motion and electrical muscle activity (EMG) to objectively quantify the severity of Parkinson's disease symptoms, such as tremor, bradykinesia (slowed movements) and dyskinesias (wild, involuntary movements). Patients follow on screen video instruction while data is wirelessly transmitted to a computer to enhance user safety and comfort.

"Objective quantification of Parkinson's disease symptoms such as tremor, bradykinesia, and dyskinesias is important in light of new pharmaceutical trials and novel therapies such as deep brain stimulation," said Dr. Alberto Espay, Neurologist at the University of Cincinnati Movement Disorders Center. "The technology should prove useful for quantifying symptoms in-clinic and tracking symptom fluctuation patterns at patients' homes to more effectively modulate treatments, ultimately improving quality of life for individuals with Parkinson's disease."

A previous clinical study involving 60 Parkinson's patients showed good correlation between Kinesia and the UPDRS. The UPDRS, a subjective assessment scale, is the current standard in rating Parkinson's symptom severity. "Kinesia is being developed as a standardized platform to measure motor symptoms and meets the clinical need for quantifying and tracking symptoms more objectively," said Joseph P. Giuffrida, PhD, Director of CleveMed's Division of Movement Disorders. "Using Kinesia with the UPDRS will give clinicians detailed information for basing treatment options, such as medication dosage and timing." This funding will be used to upgrade the system for home use, further validate correlations between Kinesia and the UPDRS and demonstrate efficacy of home monitoring over longer periods of time, such as days, weeks or months, instead of just the snapshot that clinicians see in a typical office exam.

About CleveMed - CleveMed was founded with the goal of developing innovative telemetry devices for a variety of medical applications. Today, CleveMed is developing and pioneering the use of novel wireless monitoring systems for high growth neurology and rehabilitation applications, including brain monitoring, sleep disorders and movement disorders. Through these

innovations, CleveMed has developed a growing range of products that address the needs of the medical, research and academic communities.

Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
(Date:11/25/2015)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... of Neurocrine Biosciences, will be presenting at the 27th ... York . .   ... minutes prior to the presentation to download or install ... be available on the website approximately one hour after ...
(Date:11/25/2015)... ... 25, 2015 , ... A long-standing partnership between the Academy ... been formalized with the signing of a Memorandum of Understanding. , AMA Executive ... Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA Headquarters ...
(Date:11/25/2015)... , November 25, 2015 ... Research Report is a professional and in-depth study ...      (Logo: ) , ... of the industry including definitions, classifications, applications and ... provided for the international markets including development trends, ...
(Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
Breaking Biology News(10 mins):